CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
The theme of this year’s European Headache Congress, held on 4-7 December 2024 in Rotterdam, The Netherlands and online, was ‘Towards a better headache treatment for everyone’.
Novel agents targeting the vasoactive signalling molecule, pituitary adenylate cyclase-activating polypeptide (PACAP), may be used as an alternative to anti-CGRP therapies or in combination, if promising initial results are confirmed, suggested Professor Messoud Ashina, Copenhagen University Hospital, Copenhagen, Denmark, during his plenary lecture at the congress.1 This follows new data showing that PACAP-28, one of …
Read more »New data from the Phase 3 SPACE trial show that fremanezumab significantly reduced monthly migraine days (MMD) in children and adolescents aged 6-17 years with episodic migraine and there were no emergent safety signals. In the study of 237 participants, there was a significantly greater reduction in MMD with fremanezumab than placebo at 12 weeks …
Read more »Further evidence of migraine reduction with CGRP mAbs following a drug holiday comes from a retrospective, open-label, real world study of 337 outpatients treated from 2019 to 2023. Of these, 175 were treated with erenumab, 93 with galcanezumab, and 69 with fremanezumab. At baseline, monthly migraine days (MMDs) were 21 ± 7.2, with a median …
Read more »Approximately one in three women with menstrual migraine reported positive responses to gepant treatment in a real world survey of adult patients prescribed gepants at the Jefferson Headache Center, Philadelphia, USA, between June 2020 and July 2024. Of 3545 invitations to participate, 478 (13.4%) individuals (age 49.9±14.5 years, 429 (89.7%) Caucasian, 19 (4.0%) African American) …
Read more »CGRP mAb therapy appears safe and effective in patients with migraine and comorbid autoimmune disease (AD)1,2 and in patients taking immunosuppressant drugs,3 and such comorbidities and medication use should not preclude CGRP mAb treatment. However, further research is needed on the full clinical implications. These were the conclusions of the authors of a series of studies …
Read more »As many as half of patients taking CGRP mAbs may report constipation but much depends on constipation history, and few patients need to stop treatment. These are the main findings from real world studies carried out in the UK and Portugal.1,2 In the UK single-centre, retrospective audit of patients with chronic, refractory migraine who received …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
